WO2019237400A1 - CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA - Google Patents

CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA Download PDF

Info

Publication number
WO2019237400A1
WO2019237400A1 PCT/CN2018/091733 CN2018091733W WO2019237400A1 WO 2019237400 A1 WO2019237400 A1 WO 2019237400A1 CN 2018091733 W CN2018091733 W CN 2018091733W WO 2019237400 A1 WO2019237400 A1 WO 2019237400A1
Authority
WO
WIPO (PCT)
Prior art keywords
pssalre
gene
sgrna
crispr
cas9
Prior art date
Application number
PCT/CN2018/091733
Other languages
English (en)
French (fr)
Inventor
毛吉炎
Original Assignee
深圳市博奥康生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市博奥康生物科技有限公司 filed Critical 深圳市博奥康生物科技有限公司
Priority to PCT/CN2018/091733 priority Critical patent/WO2019237400A1/zh
Publication of WO2019237400A1 publication Critical patent/WO2019237400A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Definitions

  • the invention belongs to the technical field of gene editing, and particularly relates to a method for specifically knocking out human PSSALRE gene by CRISPR-Cas9 and its specific sgRNA.
  • PSSALRE is a proline-guided serine / threonine kinase that regulates the phosphorylation of phosphorylated dephosphorylation in the cell division cycle of eukaryotic cells. Since these kinases need to bind to cyclin proteins to have kinase activity, they are called cyclin-dependent kinases.
  • PSSALRE monomer morphology is not biologically active, it is activated after dimerization with p35 or p39 protein, and mainly plays a role in the nervous system, including nerve cell growth, axon extension, and neuronal synapse during brain development. Formation and activation, and the regulation of survival and death signals of nerve cells.
  • the latest research shows that PSSALRE is associated with worse clinical prognosis in patients with melanoma, brain tumors, breast cancer and lung cancer. Therefore, it is urgent to study the role of PSSALRE in tumorigenesis.
  • the existing technology lacks a plasmid that enhances the expression of PSSALRE gene. This has hindered the progress of related research.
  • the purpose of the present invention is to provide a method for specifically knocking out the human PSSALRE gene and its specific sgRNA based on the shortcomings and deficiencies of the prior art, a simple structure, a reasonable design, and convenient use. And designed and synthesized a set of sgRNAs that specifically targeted the PSSALRE gene by using CRISPR-Cas9 to specifically knock out the human PSSALRE gene, and ligated the sgRNA with the linear PX330 plasmid to form a vector, and the PSSALRE gene was achieved by transfecting the cells Knockout can achieve a permanent effect; it provides highly efficient sgRNA; sgRNA only needs to synthesize a small amount of polynucleotide fragments, which can be produced in large quantities.
  • the method for specifically knocking out the human PSSALRE gene and its specific sgRNA according to the present invention adopt the following technical scheme:
  • the selected sgRNA add CCGG to its 5 'end to obtain a forward oligonucleotide; according to the selected sgRNA, obtain the complementary strand of its corresponding DNA, and add AAAC to its 5' end to obtain a reverse oligonucleotide .
  • the above-mentioned forward oligonucleotide and reverse oligonucleotide were synthesized separately, and the forward and reverse sequence oligonucleotide sequences of the synthesized sgRNA oligonucleotide were denatured and annealed in pairs. After annealing, the PX330 vector could be ligated. Double-stranded annealing product.
  • the annealed sgRNA oligonucleotide double strand was ligated with the linearized PX330 plasmid to obtain the PX330-PSSALRE plasmid.
  • the invention also provides an sgRNA that specifically targets the PSSALRE gene, the sequence of which is as follows: ID NO. 1.
  • the present invention has the following advantages and effects:
  • the role of the antibody is only a temporary blocking effect, and the PSSALRE gene can be directly knocked out in the present invention to achieve a permanent effect;
  • the present invention can be used to knock out multiple coding sequences of PSSALRE;
  • Antibodies can only target extracellular targets, and the present invention can target both extracellular and intracellular targets;
  • Figure 1 is the structure of the PX330 carrier
  • Figure 2 is a T7EN1 enzyme digested sgRNA / Cas9-mediated gene specific cut of human PSSALRE, in which 1- untreated control group 293T cells, 2- experimental group 293T cells transfected with PX330-PSSALRE vector.
  • the selected sgRNA sequence (SEQ ID No. 1), add CACC to its 5 'end to obtain a forward oligonucleotide; according to the selected sgRNA, obtain its complementary strand, and add AAAC to its 5' end to obtain a reverse oligonucleotide.
  • the above-mentioned forward oligonucleotide and reverse oligonucleotide were synthesized separately, and the forward and reverse oligonucleotides of the synthesized sgRNA oligonucleotide were denatured and annealed in pairs. After annealing, a double pair that can be ligated into the PX330 vector was formed. Stranded sgRNA oligonucleotide.
  • the denaturing and annealing system is:
  • the enzyme digestion system and conditions are as follows:
  • the double-stranded sgRNA oligonucleotide that can be ligated into the PX330 vector obtained after denaturation and annealing is connected to the linearized PX330 plasmid to obtain the PX330-PSSALRE plasmid.
  • connection system is as follows:
  • the high-fidelity PCR enzyme was amplified, and the PCR cleanup was purified to obtain the PCR recovered product.
  • 100 ng was uniformly diluted to 20 ⁇ L for denaturation and annealing. The procedures were: 95 ° C, 3min; 95-85 ° C, cooling at 2 ° C / s; 85-25 ° C, cooling at 0.1 ° C / s; 4 ° C hold.
  • the present invention has the following advantages and effects:
  • the role of the antibody is only a temporary blocking effect, and the PSSALRE gene can be directly knocked out in the present invention to achieve a permanent effect;
  • the present invention can be used to knock out multiple coding sequences of PSSALRE;
  • Antibodies can only target extracellular targets, and the present invention can target both extracellular and intracellular targets;

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

提供一种CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA，该方法通过计算机模拟、计算和设计，合成了一组利用CRISPR-Cas9特异性敲除人PSSALRE基因中特异性靶向PSSALRE基因的sgRNA，并分别将该sgRNA与线性的PX330质粒连接成载体，转染细胞即可实现PSSALRE基因的敲除。

Description

CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA 技术领域
本发明属于基因编辑技术领域，特别涉及一种CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA。
 背景技术
PSSALRE是由脯氨酸引导的丝氨酸/苏氨酸激酶，对真核细胞的细胞分裂周期起磷酸脱磷酸化的调控作用。由于这类激酶需要与细胞周期素蛋白结合才具有激酶活性，因此称为周期素依赖性激酶。
 技术问题
PSSALRE单体形态不具有生物活性，其与p35或p39蛋白结合二聚化后激活，并且主要在神经系统中发挥作用，包括大脑发育过程中神经细胞的生长、轴突延伸、神经细胞突触的形成和激活以及神经细胞生存信号和死亡信号的调控等。最新的研究表明，PSSALRE与黑色素瘤、脑瘤、乳腺癌以及肺癌患者更糟糕的临床预后相关，因此对PSSALRE在肿瘤发生中作用的研究刻不容缓，但现有技术中缺乏提升PSSALRE基因表达的质粒，对相关研究的进展造成了一定的阻碍。
 技术解决方案
本发明的目的在于针对现有技术的缺陷和不足，提供一种结构简单，设计合理、使用方便的CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA，它通过计算机模拟、计算和设计、合成了一组利用CRISPR-Cas9特异性敲除人PSSALRE基因中特异性靶向PSSALRE基因的sgRNA，并分别将该sgRNA与线性的PX330质粒连接成载体，转染细胞即可实现PSSALRE基因的敲除，可实现永久的效果；提供了高效的sgRNA；sgRNA只需要小量合成多核苷酸片断，就能大批量生产的优点。
为实现上述目的，本发明采用的技术方案是 ：
本发明所述的 CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA，它采用如下的技术方案 ：
1、sgRNA 寡核苷酸的高通量设计和选择
通过在线设计平台（http://crispr-era.stanford.edu/）设计sgRNA。
2、构建 sgRNA 的寡聚核苷酸双链
根据选择的sgRNA，在其5’端加上CCGG得到正向寡核苷酸；根据选择的sgRNA，获得其对应DNA的互补链，并且在其5’端加上AAAC得到反向寡核苷酸。分别合成上述正向寡核苷酸和反向寡核苷酸，将合成的sgRNA寡聚核苷酸的正反向序列寡核苷酸序列成对变性、退火，退火之后形成可以连入PX330载体的双链退火产物。
3、sgRNA 寡聚核苷酸质粒的构建
① 线性化 PX330质粒；
② 将退火的 sgRNA 寡聚核苷酸双链与线性化 PX330质粒质粒连接获得PX330-PSSALRE质粒。
③ 转化并涂氨苄平板 (100 μg/ml)。
④ 测序鉴定阳性克隆。
⑤ 37℃摇床摇菌过夜并无内毒素抽提PX330-PSSALRE质粒。
4、转染细胞获得 PSSALRE基因敲除细胞
① 按照 Lipofectamine 3000 Transfection Reagent（Invitrogen）的操作手册，将带有对应sgRNA寡聚核苷酸的PX330-PSSALRE载体转染细胞。
②用T7EN1酶切检测和TA克隆测序确认PSSALRE基因已经被敲除。
本发明还提供了特异性靶向PSSALRE基因的sgRNA，其序列如SEQ ID NO. 1所示。
 有益效果
本发明相对于现有技术，具有如下的优点及效果：
1、抗体的作用只是暂时封闭的作用，本发明直接敲除PSSALRE基因，可以实现永久的效果；
2、抑制性受体有多种，如何利用多种抗体封闭多种抑制性受体还没有对策，本发明既可以针对PSSALRE的多个编码序列进行敲除；
3、有效的PSSALRE抗体研发困难，本发明提供了针对人PSSALRE基因的一组高效的sgRNA；
4、抗体作用只能针对细胞外靶点，本发明既可以针对胞外，也能针对胞内靶点；
5、开发抗体药物是一项费时、费力、费钱的过程，使得抗体药物昂贵等，利用sgRNA只需要小量合成多核苷酸片断，就能大批量生产。
 附图说明
图1是PX330载体的结构；
图2是T7EN1酶切鉴定sgRNA/Cas9介导的基因人PSSALRE特异性切割，其中，1-未经处理的对照组293T细胞，2-转染PX330-PSSALRE载体的实验组293T细胞。
 本发明的实施方式
下面结合实施例及附图对本发明作进一步详细的描述，但本发明的实施方式不限于此。
实施例中所使用的细胞株均购自ATCC，PX330载体购自Addgene， Bbs I酶购自Thermo，Endo-Free Plasmid Mini Kit购自Omega-biotek，Lipofectamine 3000购自Invitrogen，T4 DNA连接酶购自NEB，高保真PCR酶购自Promega。
实施例一：靶向人 PSSALRE 基因的 sgRNA 寡 聚核苷酸的合成和构建
根据选择的sgRNA序列（SEQ ID No. 1），在其5’端加上CACC得到正向寡核苷酸；根据选择的sgRNA，获得其互补链，并且在其5’端加上AAAC得到反向寡核苷酸。分别合成上述正向寡核苷酸和反向寡核苷酸，将合成的sgRNA寡聚核苷酸的正反向寡核苷酸成对变性、退火，退火之后形成可以连入PX330载体的双链sgRNA寡聚核苷酸。
变性、退火体系为 ：
2.5 μL正向寡核苷酸（100 μmol/L）
2.5 μL反向寡核苷酸（100 μmol/L）
5 μL 灭菌ddH2O
在PCR仪中按照以下程序运行：95℃，3min；95-85℃，按2℃/s降温；85-25℃，按0.1℃/s降温；4℃ hold。
实施例二：利用 CRISPR-Cas9 特异性敲除人 PSSALRE 基因
1、线性化PX330质粒。
酶切体系和条件如下 ：
2 μg PX330-PSSALRE；
1 μL FastDigest Buffer ；
1 μL Bbs I；
补足ddH2O至50 μL，37℃孵育1 h。
酶切完成后用 PCR Clean up Kit（天根）纯化。
2、将变性、退火之后获得的可以连入PX330载体的双链sgRNA寡聚核苷酸与线性化的 PX330质粒相连获得PX330-PSSALRE质粒。
连接体系如下 ：
3 μL，50 μmol/L纯化退火产物
50 μg线性化的PX330质粒
1 μL 10 × T4 Ligation Buffer
1 μL T4 DNA Ligase（NEB）
ddH2O补足至10 μL
16℃孵育过夜。
4、将上述步骤获得的连接产物转化 DH5a 感受态细胞并涂氨苄平板（100 μg/mL），并挑取克隆。
5、用测序的方法鉴定获得阳性克隆。
6、37℃摇床摇菌过夜培养阳性克隆，用Endo-Free Plasmid Mini Kit无内毒素质粒抽提试剂盒抽提质粒，获得PX330-PSSALRE质粒。
7、细胞培养与转染
① 将293T细胞接种培养于含10% FBS的DMEM培养基中。
② 在转染前分至6孔板中，待细胞融合度达到70％-80％时进行转染。
③ 按照Lipofectamine 3000 Transfection Reagent（Invitrogen）的操作手册，将2 μg的PX330-PSSALRE质粒转染至每孔细胞中，6-8小时后换液，48小时后收取细胞。
8、T7EN1 酶切检测
① 收集转染PX330-PSSALRE质粒的293T细胞，提取基因组DNA。
② 以提取的基因组DNA为模板，高保真PCR酶扩增后，PCR cleanup纯化后获得PCR回收产物。取100 ng统一稀释到20 μL进行变性、退火，程序为：95℃，3min；95-85℃，按2℃/s降温；85-25℃，按0.1℃/s降温；4℃ hold。
③ 在20 μL体系中加入T7EN1 0.3μL，37℃酶切30分钟后，加入2 μL 10× Loading Buffer，用1％的琼脂糖胶电泳检测，结果表明PSSALRE基因敲除成功，如图2所示。
 工业实用性
本发明相对于现有技术，具有如下的优点及效果：
1、抗体的作用只是暂时封闭的作用，本发明直接敲除PSSALRE基因，可以实现永久的效果；
2、抑制性受体有多种，如何利用多种抗体封闭多种抑制性受体还没有对策，本发明既可以针对PSSALRE的多个编码序列进行敲除；
3、有效的PSSALRE抗体研发困难，本发明提供了针对人PSSALRE基因的一组高效的sgRNA；
4、抗体作用只能针对细胞外靶点，本发明既可以针对胞外，也能针对胞内靶点；
5、开发抗体药物是一项费时、费力、费钱的过程，使得抗体药物昂贵等，利用sgRNA只需要小量合成多核苷酸片断，就能大批量生产。

Claims (4)

  1. CRISPR-Cas9特异性敲除人PSSALRE基因的方法以及用于特异性靶向PSSALRE基因的sgRNA，其特征在于：
    （1）所述sgRNA在PSSALRE基因上的靶序列符合5’-GN(20)GG-3’或者5’-N(21)GG-3’的序列排列规则；
    （2）所述sgRNA在PSSALRE基因上的靶序列位于基因的外显子；
    （3）所述sgRNA在PSSALRE基因上的靶序列是唯一的。
  2. 根据权利要求1所述的CRISPR-Cas9特异性敲除人PSSALRE基因的方法以及用于特异性靶向PSSALRE基因的sgRNA，其特征在于，其对应的DNA序列如序列表SEQ ID NO. 1所示。
  3. 根据权利要求 1 所述的 CRISPR-Cas9 特异性敲除人 PSSALRE 基因的方法，其特征在于 ：
    （1）权利要求1-2任意一项所述的sgRNA，在其对应DNA序列的5’端加上CACC，合成得到正向寡核苷酸；权利要求1-2任意一项所述的sgRNA，获得其对应DNA序列的互补链，并且在互补链的5’端加上AAAC合成得到反向寡核苷酸；将合成的一对互补的sgRNA寡聚核苷酸的正反向寡核苷酸成对变性、退火，形成可以连入PX330基因编辑载体的双链sgRNA寡聚核苷酸；
    （2）用线性化PX330基因编辑载体；将退火的双链sgRNA寡聚核苷酸与用Bbs I线性化PX330基因编辑载体连接获得PX330-PSSALRE载体，然后转化STBL3感受态细菌并涂氨苄平板，通过测序鉴定出阳性克隆；37℃摇床摇阳性克隆菌过夜并无内毒素抽提PX330-PSSALRE载体；
    （3）用脂质体混合PX330-PSSALRE载体，转染细胞；
    （4）用 T7EN1 酶切检测确认PSSALRE基因已经被敲除并获得基因敲除的细胞。
  4. 根据权利要求3所述的 CRISPR-Cas9 特异性敲除人 PSSALRE 基因的方法，其特征在于：步骤（3）所述的脂质体为 Lipofectamine 3000（Invitrogen）。
     
PCT/CN2018/091733 2018-06-16 2018-06-16 CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA WO2019237400A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/091733 WO2019237400A1 (zh) 2018-06-16 2018-06-16 CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/091733 WO2019237400A1 (zh) 2018-06-16 2018-06-16 CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA

Publications (1)

Publication Number Publication Date
WO2019237400A1 true WO2019237400A1 (zh) 2019-12-19

Family

ID=68842594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/091733 WO2019237400A1 (zh) 2018-06-16 2018-06-16 CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA

Country Status (1)

Country Link
WO (1) WO2019237400A1 (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105886498A (zh) * 2015-05-13 2016-08-24 沈志荣 CRISPR-Cas9特异性敲除人PCSK9基因的方法以及用于特异性靶向PCSK9基因的sgRNA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105886498A (zh) * 2015-05-13 2016-08-24 沈志荣 CRISPR-Cas9特异性敲除人PCSK9基因的方法以及用于特异性靶向PCSK9基因的sgRNA

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GenBank 11 June 2018 (2018-06-11), "Homo sapiens cyclin dependent kinase 5 (CDK5), transcript variant 2, mR- NA", Database accession no. NM_001164410.2 *
LIAN ZHENWEI ET AL: "Knocking out human PDE10A Gene By The CRISPR/Cas9 System (non official translation )", BASIC & CLINICAL MEDICINE, vol. 34, no. 4, 30 April 2014 (2014-04-30), pages 339 - 443, XP055672682, ISSN: 1001-6325 *

Similar Documents

Publication Publication Date Title
CN110551761B (zh) CRISPR/Sa-SepCas9基因编辑系统及其应用
CN109312329A (zh) 提高基因组序列修饰技术中的突变导入效率的方法、及其使用的分子复合体
CN111733159B (zh) 用于猪MBP基因敲除的sgRNA组合物及用途
CN106957857A (zh) 一种利用CRISPR/Cas9系统共同敲除山羊MSTN和FGF5基因的方法
CN110551762B (zh) CRISPR/ShaCas9基因编辑系统及其应用
WO2019237400A1 (zh) CRISPR-Cas9特异性敲除人PSSALRE基因的方法及其特异的sgRNA
CN114990093A (zh) 氨基酸序列小的蛋白序列mini rfx-cas13d
WO2019237399A1 (zh) CRISPR-Cas9特异性敲除人C2orf40基因的方法及其特异的sgRNA
WO2019237365A1 (zh) CRISPR-Cas9特异性敲除人MER6基因的方法及其特异的sgRNA
CN114058632A (zh) 基因PnCOX11及其在调控三七皂苷合成中的应用
KR20130108317A (ko) Rna 리가제로서 hspc117 분자의 용도
Tomarev et al. Molecular cloning of double-stranded cDNA from the eye lens of the frog Rana temporaria: construction of the cDNA clonotheque and identification of a clone containing the nucleotide sequences of the γ-crystallin gene: Gene bank; clone library; recombinant DNA; ophthalmology; poly (A)+ RNA
WO2019237391A1 (zh) CRISPR/Cas9 靶向敲除人 TXGP1 基因及其特异性 gRNA
CN104293786B (zh) 一对靶向绵羊SFN基因的sgRNA
CN110577970A (zh) CRISPR/Sa-SlutCas9基因编辑系统及其应用
US20220162268A1 (en) Control of and imaging techniques for protein nanoscaffolds
WO2019237392A1 (zh) CRISPR/Cas9靶向敲除人SLEB2基因及其特异性gRNA
WO2019237393A1 (zh) CRISPR/Cas9靶向敲除人PDCD1L1基因及其特异性gRNA
van Weerd et al. Regulation of vertebrate conduction system development
WO2020000458A1 (zh) 一种特异靶向人NGL基因的gRNA导向序列及其应用
WO2020000452A1 (zh) 一种靶向人NGL基因的新型RNAi干扰片段、RNAi载体及其制备方法和其应用
CN112746074A (zh) Keratin 5-IRES-eGFP敲入的hESCs细胞系的构建及诱导分化方法
CN103805605B (zh) 一对靶向绵羊DKK2基因的sgRNA
WO2019227256A1 (zh) miRNA-145过表达载体的构建及其应用
WO2019237390A1 (zh) 一种敲除人hdmx基因的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18922261

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18922261

Country of ref document: EP

Kind code of ref document: A1